



## ORIGINAL ARTICLE

## Adherence to protective mechanical ventilation in COVID-19 versus non-COVID-19-associated acute respiratory distress syndrome: Comparison between two prospective cohorts



E.V. Carvalho<sup>a,b</sup>, S.P.S. Pinto<sup>a</sup>, E.P. Gomes<sup>a,b</sup>, Ó. Peñuelas<sup>c,d</sup>, C.G. Stohler<sup>a</sup>, G.C. Arantes<sup>a</sup>, L.L. Carvalho<sup>a</sup>, R.M.F. Oliveira<sup>a</sup>, P.N. Martins<sup>a</sup>, M.M. Reboredo<sup>a,b</sup>, B.V. Pinheiro<sup>a,b,\*</sup>

<sup>a</sup> Pulmonary and Critical Care Division, University Hospital of Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil

<sup>b</sup> School of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil

<sup>c</sup> Intensive Care Unit, Hospital Universitario de Getafe, Madrid, Spain

<sup>d</sup> CIBER de Enfermedades Respiratorias, CIBERES, Madrid, Spain

Received 27 November 2022; accepted 8 January 2023

### KEYWORDS

Adherence ventilation;  
Acute respiratory distress syndrome;  
COVID-19;  
Driving pressure;  
Mechanical ventilation

### Abstract

**Objective:** To compare adherence to protective mechanical ventilation (MV) parameters in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with patients with ARDS from other etiologies.

**Design:** Multiple prospective cohort study.

**Setting:** Two Brazilian cohorts of ARDS patients were evaluated. One with COVID-19 patients admitted to two Brazilian intensive care units (ICUs) in 2020 and 2021 (C-ARDS,  $n = 282$ ), the other with ARDS-patients from other etiologies admitted to 37 Brazilian ICUs in 2016 (NC-ARDS,  $n = 120$ ).

**Patients:** ARDS patients under MV.

**Interventions:** None.

**Main variables of interest:** Adherence to protective MV (tidal volume  $\leq 8$  mL/kg PBW; plateau pressure  $\leq 30$  cmH<sub>2</sub>O; and driving pressure  $\leq 15$  cmH<sub>2</sub>O), adherence to each individual component of the protective MV, and the association between protective MV and mortality.

\* Corresponding author at: Av. Eugênio do Nascimento - s/n<sup>o</sup>, Dom Bosco, Juiz de Fora, Minas Gerais, 36038-330, Brazil.  
E-mail address: [Bruno.Pinheiro@ebserh.gov.br](mailto:Bruno.Pinheiro@ebserh.gov.br) (B.V. Pinheiro).

**Results:** Adherence to protective MV was higher in C-ARDS than in NC-ARDS patients (65.8% vs. 50.0%,  $p=0.005$ ), mainly due to a higher adherence to driving pressure  $\leq 15$  cmH<sub>2</sub>O (75.0% vs. 62.4%,  $p=0.02$ ). Multivariable logistic regression showed that the C-ARDS cohort was independently associated with adherence to protective MV. Among the components of the protective MV, only limiting driving pressure was independently associated with lower ICU mortality.

**Conclusions:** Higher adherence to protective MV in patients with C-ARDS was secondary to higher adherence to limiting driving pressure. Additionally, lower driving pressure was independently associated with lower ICU mortality, which suggests that limiting exposure to driving pressure may improve survival in these patients.

© 2023 Published by Elsevier España, S.L.U.

## PALABRAS CLAVE

Adhesión a la ventilación;  
COVID-19;  
Presión de distensión;  
Síndrome de dificultad respiratoria aguda;  
Ventilación mecánica

## Adhesión a la ventilación mecánica protectora en el síndrome de dificultad respiratoria aguda asociado a COVID-19 o asociado a otras etiologías: comparación entre dos cohortes prospectivas

### Resumen

**Objetivo:** Comparar la adhesión a la ventilación mecánica (VM) protectora en pacientes con síndrome de dificultad respiratoria aguda (SDRA) causada por COVID-19 con pacientes con SDRA de otras etiologías.

**Diseño:** Estudio de cohorte prospectivo.

**Ámbito:** Se evaluaron dos cohortes de pacientes con SDRA: 1. pacientes con COVID-19 ingresados en dos unidades de cuidados intensivos (UCI) brasileñas en 2020 y 2021 (C-ARDS,  $n=282$ ); 2. pacientes con SDRA de otras etiologías ingresados en 37 UCI brasileñas en 2016 (NC-ARDS,  $n=120$ ).

**Pacientes:** Pacientes con SDRA bajo VM invasiva.

**Intervenciones:** No.

**Variables de interés principales:** Adhesión a la VM protectora (volumen tidal  $\leq 8$  mL/kg; presión de meseta  $\leq 30$  cmH<sub>2</sub>O; y presión de distensión [PD]  $\leq 15$  cmH<sub>2</sub>O), adhesión a cada componente individual de la VM protectora, y la asociación entre la VM protectora y la mortalidad.

**Resultados:** La adhesión a la VM protectora fue mayor en la cohorte C-ARDS que en la NC-ARDS (65,8% vs. 50,0%,  $p=0,005$ ), principalmente debido a mayor adhesión a la PD  $\leq 15$  cmH<sub>2</sub>O (75,0% vs. 62,4%,  $p=0,02$ ). La regresión logística multivariable mostró que la cohorte C-ARDS se asoció de forma independiente con la adhesión a la VM protectora. Entre los componentes de la VM protectora, sólo la limitación de la PD se asoció de forma independiente con menor mortalidad en la UCI.

**Conclusión:** La mayor adhesión a la VM protectora en los pacientes con C-ARDS fue secundaria a la mayor adhesión a limitación da PD. Además, una menor PD se asoció de forma independiente a menor mortalidad en la UCI, lo que sugiere que limitar la exposición a altas PD puede mejorar la supervivencia en estos pacientes.

© 2023 Publicado por Elsevier España, S.L.U.

## Introduction

Patients with acute respiratory distress syndrome (ARDS) are particularly exposed to ventilator-induced lung injury (VILI)<sup>1,2</sup>. In these patients, only a small proportion of the lungs is aerated and these ventilated areas might be exposed to excessive strain and stress, leading to local inflammation due to mechanical transduction<sup>3,4</sup>. The use of low tidal volume ( $V_T = 6$  to  $8$  mL/kg of predicted body weight [PBW]) and the maintenance of plateau pressure ( $P_{plat} < 30$  cm H<sub>2</sub>O) might decrease mortality in ARDS patients by reducing VILI occurrence<sup>5,6</sup>.

However, limiting the  $V_T$  based on PBW normalizes the  $V_T$  to the lung size but might not guarantee protective mechanical ventilation (MV), particularly in patients with severe ARDS. In these patients, alveolar overdistension can occur at the end of inspiration even with low  $V_T$ <sup>7</sup>. Moreover, protective MV might not be guaranteed by limiting the  $P_{plat}$ , especially in patients ventilated with low levels of positive end-expiratory pressure (PEEP)<sup>7</sup>. Facing these limitations, Amato et al. proposed the driving pressure (DP) as an important parameter to guide the ventilatory strategy in ARDS patients. DP allows to adjust  $V_T$  based on the amount of preserved and aerated lung tissue, which can be better esti-

mated by the compliance of the respiratory system ( $C_{RS}$ ) than by the PBW<sup>8</sup>. Observational studies have confirmed the association between lower DP levels during MV and lower mortality in ARDS patients<sup>9,10</sup>.

Patients with severe COVID-19 may develop acute respiratory failure and frequently fulfill the criteria for ARDS according to the Berlin definition<sup>11,12</sup>. For those patients, the same principles of protective MV, including  $V_T$  of 6–8 mL/kg PBW,  $P_{plat}$  lower than 30 cm H<sub>2</sub>O, and DP lower than 15 cm H<sub>2</sub>O, are recommended for both groups of patients<sup>13</sup>.

As the COVID-19 pandemic occurred years after the description of the concepts of protective MV, we hypothesized that adherence to protective MV might be greater during the pandemic, compared with the MV applied to ARDS patients before COVID-19. To test this hypothesis, we compared the ventilatory parameters applied to ARDS patients from two cohorts, one of ARDS caused by COVID-19 (C-ARDS) and the other of ARDS with other etiologies (NC-ARDS).

## Patients and methods

### Design, settings and participants

This study compared two prospective cohorts, one of C-ARDS patients and the other of NC-ARDS patients. The C-ARDS cohort was conducted in two COVID-19 dedicated ICUs in Juiz de Fora (Minas Gerais, Brazil), from March 2020 to June 2021. In this cohort, all consecutive patients aged 18 years or older were eligible for participation if they were admitted to one of the participant ICUs with COVID-19 confirmed by RT-PCR, received invasive MV, and had ARDS defined by the Berlin criteria<sup>11</sup>. We excluded patients who had received invasive MV for more than 24 h before admission in the participating ICUs, patients who were ventilated for less than 24 h, and those for whom life-sustaining treatment was withheld.

To form the NC-ARDS cohort, we performed a secondary analysis of a prospective, observational, multicenter international cohort conducted over 30 days in 2016<sup>14</sup>. For the purpose of this analysis, patients admitted to the 37 participant Brazilian ICUs were included. Among these patients, we included those aged 18 years or older, who received invasive MV, and in whom ARDS was the reason for MV or those who developed ARDS on the first day of MV. In both cases, ARDS diagnosis was based on the Berlin criteria<sup>12</sup>. We excluded patients who were ventilated for less than 24 h, and those for whom life-sustaining treatment was withheld.

The study protocols of both cohorts followed the ethical principles of the Declaration of Helsinki and were approved by the Ethics Committees of each participant hospital and written informed consent was obtained from the patients' next of kin (protocols number: 3.949.165 and 1.443.656).

### Data collection

At admission, the following patient's characteristics were prospectively recorded: age, sex, severity scores (estimated by Simplified Acute Physiology Score III [SAPS III], in the C-ARDS cohort, and by Simplified Acute Physiology Score II [SAPS II] in the NC-ARDS cohort), cardiovascular dysfunction

and renal dysfunction defined as sequential organ failure assessment (SOFA) sub-score higher than 2 points for each respective organ.

Day 0 was defined as the first calendar day that a patient received invasive MV in a participant ICU. We did not collect ventilatory parameters on day 0, at the time of patient stabilization after orotracheal intubation and MV initiation, but only on days 1–2, given the patient's delicacy and severity, to make the reproducibility of any future study increase. The following ventilatory parameters were collected on days 1 and 2, as close as possible to 8 a.m.: ventilatory mode,  $V_T$ , respiratory rate, PEEP,  $P_{plat}$  during volume-controlled mode and maximum airway pressure ( $P_{max}$ ) during pressure-controlled modes, DP (=  $P_{plat}$  minus total PEEP or  $P_{max}$  minus total PEEP),  $C_{RS}$  (=  $V_T$  divided by DP).  $V_T$  was also expressed as  $V_T$  normalized for PBW (mL/kg PBW). The PBW was calculated by the following equations:  $PBW = 50 + 0.91 \times (\text{height expressed in cm} - 152.4)$ , for males;  $PBW = 45.5 + 0.91 \times (\text{height expressed in cm} - 152.4)$ , for females<sup>6</sup>. Arterial blood gas analysis was recorded simultaneously with the ventilatory parameters.

### Outcomes

The primary outcome was adherence to protective MV, defined by the presence of all the following three parameters:  $V_T \leq 8$  mL/kg PBW;  $P_{plat} \leq 30$  cm H<sub>2</sub>O; and  $DP \leq 15$  cm H<sub>2</sub>O. Secondary outcomes included: adherence to each individual component of the protective MV definition, ICU and hospital mortality.

### Statistical analysis

Categorical variables are reported as numbers (relative proportions) and were compared using Chi-square test. Continuous variables are reported as median (25<sup>th</sup>–75<sup>th</sup> percentile) and were compared using Mann-Whitney *U* test or *t*-test, as appropriate.

Scatterplots were used to present distributions of  $V_T$  versus  $P_{plat}$ ,  $V_T$  versus DP, PEEP versus  $P_{plat}$ , and PEEP versus DP. We chose cutoffs of 8 mL/kg PBW for  $V_T$ , 30 cm H<sub>2</sub>O for  $P_{plat}$ , and 15 cm H<sub>2</sub>O for DP, based on the definition of protective MV.  $V_T$ ,  $P_{plat}$ , DP, and PEEP on day 1 were presented in cumulative distribution plots.

A multivariate logistic model was performed considering the cohort (C-ARDS or NC-ARDS) as the independent variable of interest and the protective MV as the dependent variable. We performed a directed acyclic graph (DAG) to choose the confounders and to avoid over-adjustment of the model. We used the dagitty tool - [www.dagitty.net](http://www.dagitty.net)<sup>15</sup>. Briefly, a DAG is a graphical tool that enables the visualization of the relationships between the exposure of interest, the outcome being studied, and all other variables that are associated in some way with at least two other variables in the diagram. A comprehensive review can be found in recent reviews<sup>16,17</sup>. In this model, the following confounders were selected: age, sex,  $C_{RS}$ , ratio of arterial oxygen partial pressure to fraction of inspired oxygen ( $PaO_2/FiO_2$ ), arterial carbon dioxide partial pressure ( $PaCO_2$ ), pH, renal dysfunction (Fig. 1 in Supplementary Appendix).

**Table 1** Baseline demographic and clinical characteristics, and respiratory parameters on day 1 of mechanical ventilation and outcomes in patients from NC-ARDS and C-ARDS cohorts.

	NC-ARDS cohort (N = 120)	C-ARDS cohort (N = 228)	p
Age (years)	67 (54–80)	64 (53–74)	0.045
Male	56 (46.7%)	123 (53.9%)	0.20
PBW (kg)	60.6 (55.1–64.5)	61.5 (52.4–67.8)	0.26
SAPS-2	50.0 (41.0–65.0)		
SAPS-3		45.0 (39.5–54.0)	
ARDS severity			<0.001
Mild	41 (36.6%)	106 (46.9%)	
Moderate	48 (42.9%)	105 (46.5%)	
Severe	23 (20.5%)	15 (6.4%)	
Co-existing organ dysfunction			
Cardiovascular	66 (55.0%)	157 (68.9%)	0.01
Renal	32 (26.7%)	35 (15.4%)	0.01
Mode of ventilation			0.036
Pressure-controlled ventilation	65 (54.2%)	131 (56.3%)	
Volume-controlled ventilation	49 (40.8%)	96 (42.1%)	
Pressure-support ventilation	4 (3.3%)	1 (0.4%)	
Others	2 (1.7%)	0 (0%)	
Tidal volume, mL/kg of PBW	6.1 (5.2–7.6)	6.5 (5.9–7.2)	0.01
Peak pressure, cm H <sub>2</sub> O	25.0 (20.0–29.0)	26.0 (24.0–29.5)	<0.01
Plateau pressure, cm H <sub>2</sub> O	22 (18–26)	24 (22–27)	<0.01
Driving pressure, cm H <sub>2</sub> O	14.0 (11.0–18.0)	13.0 (11.0–15.5)	0.04
PEEP, cm H <sub>2</sub> O	8.0 (5.0–10.0)	10.0 (10.0–12.0)	<0.001
C <sub>RS</sub> , mL/cm H <sub>2</sub> O	32.1 (24.9–38.9)	30.6 (24.7–36.8)	0.48
Adherence to			
Protective MV	58 (50.0%)	150 (65.8%)	0.005
V <sub>T</sub> ≤ 8 mL/kg PBW	93 (80.2%)	198 (86.8%)	0.12
Pplat ≤ 30 cm H <sub>2</sub> O	111 (94.9%)	209 (91.7%)	0.27
DP ≤ 15 cm H <sub>2</sub> O	73 (62.4%)	171 (75.0%)	0.02
FiO <sub>2</sub>	0.60 (0.40–0.81)	0.60 (0.50–0.78)	0.64
PaO <sub>2</sub> /FiO <sub>2</sub> , mm Hg	176 (106–240)	195 (147–248)	0.01
PaCO <sub>2</sub> , mm Hg	40 (36–47)	45 (40–53)	<0.001
pH	7.34 (7.27–7.40)	7.34 (7.28–7.40)	0.98
Outcomes			
ICU mortality	63 (52.5%)	110 (48.3%)	0.45
Hospital mortality	72 (60.5%)	119 (52.2%)	0.14

Categorical variables expressed as n (%), continuous variables expressed as median (IQR).

ARDS: acute respiratory distress syndrome; C<sub>RS</sub>: compliance of the respiratory system; DP: driving pressure; FiO<sub>2</sub>: fraction of inspired oxygen; ICU: intensive care unit; IQR: interquartile range; MV: mechanical ventilation; PaCO<sub>2</sub>: arterial carbon dioxide partial pressure; PaO<sub>2</sub>/FiO<sub>2</sub>: ratio of arterial oxygen partial pressure to fraction of inspired oxygen; PBW: predicted body weight; PEEP: positive end expiratory pressure; Pplat: plateau pressure; SAPS: simplified acute physiology score.

Organ dysfunction defined by a score of 2 points or more in the respective domain of the sequential organ failure assessment (SOFA).

Numbers and percentages of missing data, and their distribution across both cohorts are shown in Table 1 in Supplementary Appendix.

Another multivariate logistic model was performed considering non-adherence to protective MV as the independent variable of interest and ICU mortality as the dependent variable. For this analysis, another DAG was drawn and the following confounders were selected: age, sex, C<sub>RS</sub>, PaO<sub>2</sub>/FiO<sub>2</sub>, PaCO<sub>2</sub>, pH, cardiovascular and renal dysfunction (Fig. 2 in Supplementary Appendix). The same model was applied considering non-adherence to protective MV as the independent variable of interest and hospital mortality as the dependent variable.

All analyses were conducted with Stata 15.1 (Stata Corp LP, College Station, TX, USA), and significance level was set at 0.05.

## Results

Overall 120 of 902 patients admitted to 37 Brazilian ICUs that participated in the original cohort study met the Berlin criteria for ARDS diagnosis at admission or on the first day of MV and constituted the NC-ARDS cohort. The C-ARDS cohort




Figure 1 Study participant flow chart.





Figure 2 Ventilatory parameters on the first day of mechanical ventilation in C-ARDS and NC-ARDS patients. Cumulative frequency distribution of tidal volume, mL/kg PBW (A), plateau pressure, cm H<sub>2</sub>O (B); driving pressure, cm H<sub>2</sub>O (C); positive end expiratory pressure, cm H<sub>2</sub>O (D). Vertical dotted lines represent the respective cutoffs for tidal volume, plateau pressure and driving pressure. Horizontal dotted line represents the median of applied PEEP.



**Figure 3** Distribution of ventilatory parameters on the first day of mechanical ventilation in C-ARDS and NC-ARDS patients. Distribution of tidal volume, mL/kg PBW against plateau pressure, cm H<sub>2</sub>O (A) and driving pressure, cm H<sub>2</sub>O (B). Distribution of PEEP, cm H<sub>2</sub>O against plateau pressure, cm H<sub>2</sub>O (C) and driving pressure, cm H<sub>2</sub>O (D). Dotted lines represent the respective cutoffs for each variable.

ARDS: acute respiratory distress syndrome; C-ARDS: COVID-19 acute respiratory distress syndrome; NC-ARDS: acute respiratory distress syndrome from other etiologies; PEEP: positive end expiratory pressure; PBW: predicted body weight.

was constituted of 228 patients admitted to two COVID-19 dedicated ICUs (Fig. 1).

Table 1 shows demographic and clinical characteristics, and respiratory parameters on day 1 of MV in both cohorts. Patients with C-ARDS were younger and presented severe form of ARDS less frequently. At baseline, a higher proportion of patients with C-ARDS presented cardiovascular dysfunction and a lower proportion presented renal dysfunction, compared with patients with NC-ARDS. C-ARDS patients received higher V<sub>T</sub> and higher PEEP levels, they presented higher P<sub>plat</sub> and higher PaO<sub>2</sub>/F<sub>i</sub>O<sub>2</sub> compared with patients with NC-ARDS. C-ARDS patients presented lower DP compared with patients with NC-ARDS. Similar results were found on day 2 of MV and they are shown in Table 2 in Supplementary Appendix.

Protective MV, as defined by the three parameters (V<sub>T</sub> ≤ 8 mL/kg PBW; P<sub>plat</sub> ≤ 30 cm H<sub>2</sub>O; and DP ≤ 15 cm H<sub>2</sub>O), was applied to 65.8% of C-ARDS patients and to 50.0% of the NC-ARDS patients (p = 0.005) on day 1 of MV. V<sub>T</sub> was lower than 8.0 mL/kg PBW in 86.8% in C-ARDS and in 80.2% in NC-ARDS (p = 0.12) on day 1 of MV. The proportion of patients with P<sub>plat</sub> ≤ 30 cm H<sub>2</sub>O was 91.7% in C-ARDS and 94.9% in NC-ARDS (p = 0.28), and the proportion of patients with DP ≤ 15 cm

**Table 2** Multivariable logistic regression assessing the association between C-ARDS cohort and non-protective mechanical ventilation on day 1.

	Multivariable odds ratio (95% CI)	p
C-ARDS cohort	0.58 (0.34–0.99)	0.047
Age	0.99 (0.98–1.02)	0.927
Female	1.23 (0.74–2.05)	0.419
C <sub>RS</sub>	0.93 (0.90–0.96)	<0.001
PaO <sub>2</sub> /FiO <sub>2</sub>	1.00 (0.99–1.00)	0.072
PaCO <sub>2</sub>	0.97 (0.94–0.99)	0.014
pH	1.01 (0.98–1.04)	0.616
Renal dysfunction	1.11 (0.58–2.12)	0.756

C-CARDS: acute respiratory distress syndrome due to COVID-19, CI: confidence interval, C<sub>RS</sub>: compliance of the respiratory system, PaO<sub>2</sub>/FiO<sub>2</sub>: ratio of arterial oxygen partial pressure to fraction of inspired oxygen; PaCO<sub>2</sub>: arterial carbon dioxide partial pressure.

**Table 3** Multivariable logistic regression assessing the association between protective mechanical ventilation and driving pressure in C-ARDS and NC-ARDS cohorts, on day 1 and ICU-mortality.

	Protective MV as the independent variable of interest		Driving pressure as the independent variable of interest	
	Odds ratio (95% CI)	<i>p</i>	Odds ratio (95% CI)	<i>p</i>
Protective MV	0.74 (0.44–1.25)	0.269		
Driving pressure			1.11 (1.00–1.23)	0.046
Age	1.03 (1.02–1.05)	<0.001	1.03 (1.02–1.05)	<0.001
Female	0.56 (0.34–0.94)	0.030	0.64 (0.38–1.09)	0.10
C <sub>RS</sub>	0.97 (0.95–1.00)	0.065	1.00 (0.96–1.04)	0.79
PaO <sub>2</sub> /FiO <sub>2</sub>	0.99 (0.99–1.00)	0.061	0.99 (0.99–1.00)	0.07
PaCO <sub>2</sub>	0.96 (0.94–0.99)	0.008	0.97 (0.94–0.99)	0.02
pH	0.95 (0.92–0.98)	0.002	0.95 (0.92–0.98)	0.002
Cardiovascular dysfunction	1.60 (0.95–2.69)	0.072	1.70 (1.00–2.88)	0.046
Renal dysfunction	1.41 (0.74–2.68)	0.293	1.42 (0.74–2.71)	0.28

CI: confidence interval, C<sub>RS</sub>: compliance of the respiratory system; MV: mechanical ventilation, PaO<sub>2</sub>/FiO<sub>2</sub>: ratio of arterial oxygen partial pressure to fraction of inspired oxygen; PaCO<sub>2</sub>: arterial carbon dioxide partial pressure.

H<sub>2</sub>O was 75.0% in C-ARDS and 62.4% in NC-ARDS ( $p = 0.02$ ) on day 1 of MV (Table 1 and Fig. 2). Fig. 3 shows the distributions of DP and P<sub>plat</sub> in different V<sub>T</sub> and PEEP levels. Multivariable logistic regression showed that the C-ARDS cohort was independently associated with protective MV on day 1 (Table 2).

On day 2 of MV, protective MV was applied to 67.1% of C-ARDS patients and to 42.0% of the NC-ARDS patients ( $p < 0.001$ ). On day 2, the proportions of patients ventilated with V<sub>T</sub> > 8 mL/kg PBW or with P<sub>plat</sub> > 30 cm H<sub>2</sub>O were similar between the two cohorts. However, 75.4% of C-ARDS patients presented DP ≤ 15 cm H<sub>2</sub>O compared to 53.9% of NC-ARDS patients ( $p < 0.001$ ) (Table 3, Figs. 3 and 4 in Supplementary Appendix).

There was neither significant difference in ICU mortality between C-ARDS and NC-ARDS cohorts (48.3% vs. 52.5%, respectively,  $p = 0.45$ ), nor in hospital mortality (52.2% vs. 60.5%, respectively,  $p = 0.14$ ) (Table 1). Protective MV (V<sub>T</sub> ≤ 8 mL/kg PBW; P<sub>plat</sub> ≤ 30 cm H<sub>2</sub>O; and DP ≤ 15 cm H<sub>2</sub>O) was not independently associated with lower ICU mortality (Table 3) and hospital mortality (Table 5 in Supplementary Appendix) in both cohorts. Among the individual components of the protective MV definition, there was a significant association between DP ≤ 15 cm H<sub>2</sub>O and ICU mortality (Table 3). However, there were no significant associations between V<sub>T</sub> ≤ 8 mL/kg PBW or P<sub>plat</sub> ≤ 30 cm H<sub>2</sub>O and ICU mortality (Table 4 in Supplementary Appendix).

## Discussion

In this observational study, which compared two prospective Brazilian cohorts of ARDS patients (C-ARDS and NC-ARDS), we found that a greater proportion of patients with C-ARDS received protective MV, compared with NC-ARDS patients. Multivariable analysis showed that the C-ARDS cohort was independently associated with protective MV. The higher adherence to protective MV in the C-ARDS cohort occurred mainly due to a higher proportion of patients with DP equal to or lower than 15 cm H<sub>2</sub>O. Among the three individual

components of the protective MV, only driving pressure was independently associated with ICU mortality.

The first clinical studies demonstrating that a protective MV could reduce mortality in ARDS patients were based on limiting V<sub>T</sub> and P<sub>plat</sub><sup>5,6</sup>. In our study, the proportion of patients with these two parameters on safe levels was similar between the two cohorts, and in accordance with recent studies in C-ARDS and NC-ARDS patients<sup>9,18,19</sup>. These findings might reflect progressive incorporation of ventilatory strategies aimed at reducing VILI throughout the last two decades, as demonstrated by Peñuelas et al.<sup>14</sup>. These authors evaluated four cohorts of mechanically ventilated patients (1998, 2004, 2010, and 2016) and showed a significant increase in the use of protective MV over time. Moreover, they showed that 28-day mortality decreased significantly and that a lung protective strategy mediated an important fraction of the effect of temporal evolution on mortality.

More recently, DP has been considered an important ventilatory variable in the protective ventilatory strategy. Firstly, Amato et al. analyzed data from ARDS patients enrolled in previous randomized trials and demonstrated that DP was the ventilation variable best associated with mortality<sup>8</sup>. Since then, other authors have demonstrated an association between DP and mortality in ARDS patients of different etiologies<sup>10,20,21</sup>, including ARDS due to COVID-19<sup>18,22</sup>. In our study, C-ARDS patients presented lower DP than NC-ARDS patients, and a higher proportion of patients in the C-ARDS cohort presented DP equal to or lower than 15 cm H<sub>2</sub>O. This difference was responsible for the higher adherence to protective MV in the C-ARDS cohort. It might have occurred due to progressive incorporation of the DP as a protective ventilatory parameter over the years that separate the two cohorts. Moreover, the C-ARDS cohort was formed with patients admitted to two COVID-19 dedicated ICUs over 18 months, i.e. patients with a single clinical condition, a fact that might have improved compliance to protective MV.

ICU and hospital mortality were similar between the two cohorts and in line with mortality rates observed in pre-

vious studies of ARDS patients due to COVID-19 or other causes<sup>9,22-25</sup>. In our analysis, the association between protective MV and ICU mortality did not reach statistical significance. When each component of the protective MV was analyzed separately, DP but not  $V_T$  and  $P_{plat}$  was independently associated with ICU mortality. This may have occurred because most patients were ventilated with  $V_T$  lower than 8 mL/kg PBW and  $P_{plat}$  lower than 30 cm H<sub>2</sub>O, leading to insufficient statistical power to detect an association between these variables and mortality. DP presented a broader distribution, especially in the NC-ARDS cohort, which may have happened because the role of DP in protective MV has been described more recently. Another possible explanation for these findings is that once DP is kept under safe levels, the importance of  $V_T$  and  $P_{plat}$  as protective variables decreases<sup>26</sup>.

Our study has several relevant limitations. 1. The C-ARDS cohort was formed in only two COVID-19 dedicated ICUs, whereas the NC-ARDS cohort was formed in 37 ICUs from different Brazilian states. Therefore, the NC-ARDS cohort better represents the ventilatory practices in Brazil, compared to the C-ARDS cohort. 2. NC-ARDS was formed over only one month, and C-ARDS cohort was formed over 18 months, during which time adherence to protective MV may have progressively increased. 3. Ventilatory parameters were collected only on the first two days of MV and may not represent those applied during the following days. We cannot exclude the possibility that ventilatory parameters applied beyond day 2 influenced the mortality. 4. Not all clinical variables possibly associated with protective MV or mortality were collected, a fact that might have limited the precision of the DAGs that were drawn for the multivariable analyses. 5. Different disease severity scores were applied in each cohort (SAPS-3 in C-ARDS, SAPS-II in NC-ARDS), consequently they could not be compared.

In conclusion, we observed a higher adherence to protective MV among C-ARDS patients, mainly secondary to higher adherence to limiting DP. Incorporating DP in the protective MV seems to be important, since, among the three components of the protective MV, DP was the one best associated with mortality. However, to ascertain a causal relationship between DP and mortality in ARDS patients, randomized clinical trials are necessary.

## Authors' contribution

- Erich V. Carvalho: conception and design of the study, acquisition of data, analysis and interpretation of data, literature search, drafting the article, final approval of the version to be published.
- Sérgio P. S. Pinto: conception and design of the study, acquisition of data, analysis and interpretation of data, literature search, drafting the article, final approval of the version to be published.
- Edimar P. Gomes: conception and design of the study, acquisition of data, analysis and interpretation of data, literature search, drafting the article, final approval of the version to be published.
- Óscar Peñuelas: conception and design of the study, analysis and interpretation of data, revising the article providing intellectual content of critical importance to

the work described, final approval of the version to be published.

- Caio G. Stohler: acquisition of data, analysis and interpretation of data, revising the article providing intellectual content of critical importance to the work described, final approval of the version to be published.
- Gustavo C. Arantes: acquisition of data, analysis and interpretation of data, revising the article providing intellectual content of critical importance to the work described, final approval of the version to be published.
- Lucas L. Carvalho: acquisition of data, analysis and interpretation of data, revising the article providing intellectual content of critical importance to the work described, final approval of the version to be published.
- Roberta M. F. Oliveira: acquisition of data, analysis and interpretation of data, revising the article providing intellectual content of critical importance to the work described, final approval of the version to be published.
- Pedro N. Martins: acquisition of data, analysis and interpretation of data, revising the article providing intellectual content of critical importance to the work described, final approval of the version to be published.
- Maycon M. Reboredo: conception and design of the study, analysis and interpretation of data, drafting the article, final approval of the version to be published.
- Bruno V. Pinheiro: conception and design of the study, analysis and interpretation of data, drafting the article, final approval of the version to be published.

## Funding

This study was supported by a National Council for Scientific and Technological Development – CNPq.

## Declarations of interest

None.

## Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.medin.2023.01.001>.

## References

1. Bates JHT, Smith BJ. Ventilator-induced lung injury and lung mechanics. *Ann Transl Med.* 2018;6:378–90, <http://dx.doi.org/10.21037/atm.2018.06.29>.
2. Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. *Lancet.* 2021;398:622–37, [http://dx.doi.org/10.1016/S0140-6736\(21\)00439-6](http://dx.doi.org/10.1016/S0140-6736(21)00439-6).
3. Gattinoni L, Pesenti A. The concept of baby lung. *Intensive Care Med.* 2005;31:776–84, <http://dx.doi.org/10.1007/s00134-015-4200-8>.
4. Marini JJ, Rocco PRM, Gattinoni L. Static and dynamic contributors to ventilator-induced lung injury in clinical practice. Pressure, energy, and power. *Am J Respir Crit Care Med.* 2020;201:767–74, <http://dx.doi.org/10.1164/rccm.201908-1545CI>.
5. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, et al. Effect of a protective-



- ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med.* 1998;338:347–54, <http://dx.doi.org/10.1056/NEJM199802053380602>.
6. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med.* 2000;342:1301–8, <http://dx.doi.org/10.1056/NEJM200005043421801>.
  7. Terragni PP, Rosboch G, Tealdi A, Corno E, Menaldo E, Davini O, et al. Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. *Am J Respir Crit Care Med.* 2007;175:160–6, <http://dx.doi.org/10.1164/rccm.200607-915OC>.
  8. Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med.* 2015;372:747–55, <http://dx.doi.org/10.1056/NEJMsa1410639>.
  9. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA.* 2016;315:788–800, <http://dx.doi.org/10.1001/jama.2016.0291>.
  10. Urner M, Jüni P, Hansen B, Wettstein MS, Ferguson ND, Fan E. Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study. *Lancet Respir Med.* 2020;8:905–13, [http://dx.doi.org/10.1016/S2213-2600\(20\)30325-8](http://dx.doi.org/10.1016/S2213-2600(20)30325-8).
  11. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA.* 2012;307:2526–33, <http://dx.doi.org/10.1001/jama.2012.5669>.
  12. Hernández-Cárdenas C, Lugo-Goytia G, Hernández-García D, Pérez-Padilla R. Comparison of the clinical characteristics and mortality in acute respiratory distress syndrome due to COVID-19 versus due to Influenza A-H1N1pdm09. *Med Intensiva.* 2022;46:345–7, <http://dx.doi.org/10.1016/j.medine.2021.05.006>.
  13. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Crit Care Med.* 2020;48:e440–469, <http://dx.doi.org/10.1097/CCM.0000000000004363>.
  14. Peñuelas O, Muriel A, Abraira V, Frutos-Vivar F, Mancebo J, Raymondos K, et al. Inter-country variability over time in the mortality of mechanically ventilated patients. *Intensive Care Med.* 2020;46:444–53, <http://dx.doi.org/10.1007/s00134-019-05867-9>.
  15. Textor J, van der Zander B, Gilthorpe MS, Liskiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package 'dagitty'. *Int J Epidemiol.* 2016;45:1887–94, <http://dx.doi.org/10.1093/ije/dyw341>.
  16. Suttorp MM, Siegerink B, Jager KJ, Zoccali C, Dekker FW. Graphical presentation of confounding in directed acyclic graphs. *Nephrol Dial Transplant.* 2015;30:1418–23, <http://dx.doi.org/10.1093/ndt/gfu325>.
  17. Staplin N, Herrington WG, Judge PK, Reith CA, Haynes R, Landray MJ, et al. Use of causal diagrams to inform the design and interpretation of observational studies: an example from the Study of Heart and Renal Protection (SHARP). *Clin J Am Soc Nephrol.* 2017;12:546–52, <http://dx.doi.org/10.2215/CJN.02430316>.
  18. Ferreira JC, Ho YL, Besen BAMP, Malbouisson LMS, Taniguchi LU, Mendes PV, et al. Protective ventilation and outcomes of critically ill patients with COVID-19: a cohort study. *Ann Intensive Care.* 2021;11:92–102, <http://dx.doi.org/10.1186/s13613-021-00882-w>.
  19. Botta M, Tsonas AM, Pillay J, Boers LS, Algera AG, Bos LDJ, et al. Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PROVENT-COVID): a national, multicentre, observational cohort study. *Lancet Respir Med.* 2021;9:139–48, [http://dx.doi.org/10.1016/S2213-2600\(20\)30459-8](http://dx.doi.org/10.1016/S2213-2600(20)30459-8).
  20. Chen L, Grieco DL, Beloncle F, Chen GQ, Tiribelli N, Madotto F, et al. Partition of respiratory mechanics in patients with acute respiratory distress syndrome and association with outcome: a multicentre clinical study. *Intensive Care Med.* 2022;48:888–98, <http://dx.doi.org/10.1007/s00134-022-06724-y>.
  21. Dianti J, Matelski J, Tisminetzky M, Walkey AJ, Munshi L, Del Sorbo L, et al. Comparing the effects of tidal volume, driving pressure, and mechanical power on mortality in trials of lung-protective mechanical ventilation. *Respir Care.* 2021;66:221–7, <http://dx.doi.org/10.4187/respcare.07876>.
  22. Estenssoro E, Loudet CI, Ríos FG, Kanoore Edul VS, Plotnikow G, Andrian M, et al. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study. *Lancet Respir Med.* 2021;9:989–98, [http://dx.doi.org/10.1016/S2213-2600\(21\)00229-0](http://dx.doi.org/10.1016/S2213-2600(21)00229-0).
  23. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med.* 2020;180:1345–55, <http://dx.doi.org/10.1001/jamainternmed.2020.3539>.
  24. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. *Lancet Respir Med.* 2020;8:853–62, [http://dx.doi.org/10.1016/S2213-2600\(20\)30316-7](http://dx.doi.org/10.1016/S2213-2600(20)30316-7).
  25. Madotto F, Pham T, Bellani G, Bos LD, Simonis FD, Fan E, et al. Resolved versus confirmed ARDS after 24 h: insights from the LUNG SAFE study. *Intensive Care Med.* 2018;44:564–77, <http://dx.doi.org/10.1007/s00134-018-5152-6>.
  26. Sahetya SK, Mancebo J, Brower RG. Fifty years of research in ARDS. Vt selection in acute respiratory distress syndrome. *Am J Respir Crit Care Med.* 2017;196:1519–25, <http://dx.doi.org/10.1164/rccm.201708-1629CI>.